The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Analysis Demonstrates Long-Term Safety Profile of Filgotinib for RA Treatment
The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.
Abiprubart Reduces Disease Activity in Refractory Rheumatoid Arthritis
Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.
8 out of 10 Patients with RA Achieve Sustained Remission at Month 12 with Upadacitinib
Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.
Filgotinib Demonstrates Early, Durable PRO Improvements in RA
A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.
Total Fish Intake in Pregnancy Could Alter Risk of Juvenile Arthritis in Offspring
EULAR 2024 data link maternal intake of over 252 grams of fish per week with higher risk of juvenile idiopathic arthritis in offspring, but causation is unclear.
Brian LaMoreaux, MD: Defining and Achieving Remission in Gout with Pegloticase
A post hoc analysis of the MIRROR trial suggests comprehensive gout management should aim for remission, incorporating both uric acid lowering and broader symptom improvements.
Frederic Lavie, MD, PhD: Guselkumab Provides Robust Improvements in Pain Among Patients with PsA
Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.
Frederic Lavie, MD, PhD: Guselkumab Demonstrates Rapid, Sustained Improvements in Severe PsA
Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis, which were maintained through 2 years.
Frederic Lavie, MD, PhD: cDAPSA Demonstrates Efficacy in Monitoring Disease Activity in PsA
Results revealed cDAPSA can help providers accurately measure the level of disease activity in patients and predict whether the patient will have radiographic progression.
Phase 3 Upadacitinib Trial Shows Promising Results for Giant Cell Arteritis Treatment
Daniel Blockmans, MD, PhD, discussed the results of a phase 3 trial that revealed upadacitinib significantly improved outcomes in patients with giant cell arteritis.
TNX-102 SL Significantly Reduces Daily Pain, Improves Fibromyalgia Symptoms
At EULAR, Tonix Pharmaceuticals presented the phase 3 RESILIENT trial which met the primary endpoint of TNX-102 SL reducing daily pain intensity.
Connective Tissue Disease Brings Dermatology & Rheumatology Together
Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.
Karen Costenbader, MD: Data Supports Belimumab as Treatment in Early Lupus
Karen Costenbader, MD, discusses the 2 post hoc analyses that demonstrated treatment with belimumab reduces flares and increases response rates among patients with early active SLE.
Twice-Daily Delgocitinib Improved Patient Reported Outcomes for Chronic Hand Eczema
These data, presented at RAD 2024, highlight the potential of delgocitinib cream for patients with chronic hand eczema in terms of patient and clinician reported outcomes.
Benefits of Early Belimumab Intervention in SLE, with Karen Costenbader, MD
Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.
Risk of Malignancy, Major Adverse Cardiovascular Events in Patients with Atopic Dermatitis
These findings, presented at RAD 2024, highlight risk of atopic dermatitis patients for developing various cancers as well as major adverse cardiovascular events.
Spesolimab Rapidly Improves QoL in Generalized Pustular Psoriasis
Patients in the spesolimab cohort demonstrated rapid improvements in DLQI scores compared with placebo, which were maintained through week 48.
Certolizumab Pegol Offers Consistent Benefit, Regardless of Rheumatoid Factor Levels
An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.
Dupilumab Versus Lebrikizumab with Topical Corticosteroids: Efficacy in Atopic Dermatitis
These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.
What Makes JAK Inhibitors Safe in Dermatology
Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.
Potential JAK Inhibitor Combination Regimens in Dermatology
Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.
Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients
These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.
Bimekizumab Response is Sustained Over 4 Years in Plaque Psoriasis
Responses were highly durable throughout 4 years of bimekizumab treatment.
Therapies in Development for Hidradenitis Suppurativa
Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.
"Prednisone Without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.
Halobetasol Propionate, Tazarotene Lotion Demonstrates Clinically Significant Skin Clearance in Hyperkeratotic Psoriasis
Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.
Moderate-to-Severe Alopecia Areata Patients More Likely Than Mild Cases to Develop Eczema
In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.
Brodalumab Demonstrates Efficacy, Safety in Moderate to Severe Psoriasis
Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
Bourjeily told HCPLive at SLEEP 2024 that sleep issues, such as insomnia and restless legs syndrome, are the most common during the first and third trimester of pregnancy.